Goodman Corey S's Form 4 filing
Checkmate Pharmaceuticals, Inc. (CMPI) · filed May 4, 2022
- Accession no.
- 0001567619-22-009528
- Filed
- May 4, 2022, 7:30 PM ET
- Trade date
- May 2-4, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions and 0 derivative transactions. Open-market sales total $2.81M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Goodman Corey SCIK 0001278411 | 10% Owner |
| Adelman Robert JCIK 0001329161 | 10% Owner |
| venBio Global Strategic Fund II L.P.CIK 0001634632 | 10% Owner |
| venBio Global Strategic GP II, Ltd.CIK 0001729408 | 10% Owner |
| venBio Global Strategic GP II, L.P.CIK 0001729409 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 2, 2022 | Common Stock | SSaleDisposed | −153,700 | $10.38 | −$1,595,974.69 | 2,652,133 | Direct | |
| May 3, 2022 | Common Stock | SSaleDisposed | −79,475 | $10.37 | −$824,433.91 | 2,572,658 | Direct | |
| May 4, 2022 | Common Stock | SSaleDisposed | −37,500 | $10.37 | −$388,923.75 | 2,535,158 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.